{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:49:16Z","timestamp":1764776956651,"version":"3.46.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","award":["contract nr EMA\/2018\/18\/PE"],"award-info":[{"award-number":["contract nr EMA\/2018\/18\/PE"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Ther Perspect"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40267-025-01207-8","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:14:05Z","timestamp":1763730845000},"page":"568-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Knowledge, Awareness, and Attitudes of Healthcare Professionals and Patients Regarding Pregnancy Prevention Programmes: A Survey and Interview-Based Case Study on Valproates in Portugal"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5712-1338","authenticated-orcid":false,"given":"Paula","family":"Sousa-Ferreira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8158","authenticated-orcid":false,"given":"In\u00eas","family":"Ribeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-1916","authenticated-orcid":false,"given":"Teresa Leonardo","family":"Alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-8085","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Rocha","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-9993","authenticated-orcid":false,"given":"Carla","family":"Torre","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1207_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0197-0186(00)00013-9","volume":"37","author":"CU Johannessen","year":"2000","unstructured":"Johannessen CU. Mechanisms of action of valproate: a commentary. Neurochem Int. 2000;37:103\u201310.","journal-title":"Neurochem Int"},{"key":"1207_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/1039856220934317","volume":"28","author":"R Goldspink","year":"2020","unstructured":"Goldspink R, Pumipi T, Dey S, Menkes DB. Sodium valproate prescription to women of childbearing age in a New Zealand inpatient psychiatric unit. Australas Psychiatry. 2020;28:555\u20138.","journal-title":"Australas Psychiatry"},{"issue":"3","key":"1207_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/pds.5166","volume":"30","author":"M Toussi","year":"2021","unstructured":"Toussi M, Shlaen M, Coste F, de Voogd H, Dimos V, Kaplan S. Effectiveness of risk minimisation measures for valproate: a drug utilisation study in Europe. Pharmacoepidemiol Drug Saf. 2021;30(3):292\u2013303.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1207_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40264-023-01314-3","volume":"46","author":"S Abtahi","year":"2023","unstructured":"Abtahi S, Pajouheshnia R, Dur\u00e1n CE, Riera-Arnau J, Gamba M, Alsina E, et al. Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of medicinal products containing valproate: an interrupted time series study. Drug Saf. 2023;46:689\u2013702.","journal-title":"Drug Saf"},{"key":"1207_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","volume":"81","author":"K Meador","year":"2008","unstructured":"Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81:1\u201313.","journal-title":"Epilepsy Res"},{"key":"1207_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/adc.2009.176990","volume":"96","author":"C Cummings","year":"2011","unstructured":"Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011;96:643\u20137.","journal-title":"Arch Dis Child"},{"key":"1207_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010224.pub2","author":"J Weston","year":"2016","unstructured":"Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD010224.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1207_CR8","unstructured":"European Medicines Agency. CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls. EMA\/709243\/2014. London: EMA; 2014. p. 1\u20134."},{"key":"1207_CR9","unstructured":"European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. EMA\/375438\/2018. London: EMA; 2018. p. 1\u20133."},{"key":"1207_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20032215","volume":"20","author":"NMB Oliveri","year":"2023","unstructured":"Oliveri NMB, Hansen JM, Almarsd\u00f3ttir AB, Jacobsen R. The awareness and adherence of the valproate pregnancy prevention program: a questionnaire survey among healthcare professionals, pharmacists, and patients in Denmark. Int J Environ Res Public Health. 2023;20:2215.","journal-title":"Int J Environ Res Public Health"},{"key":"1207_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000433","volume":"5","author":"MM Watila","year":"2023","unstructured":"Watila MM, James A, Milne K, Mackay G. Valproate pregnancy prevention scheme: what are the barriers to enrolling patients and how do we meet them? BMJ Neurol Open. 2023;5:e000433.","journal-title":"BMJ Neurol Open"},{"key":"1207_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/pharmacy12060182","volume":"12","author":"M \u0160po\u0123e","year":"2024","unstructured":"\u0160po\u0123e M, Kurs\u012bte M, Poplavska E. Latvian healthcare professionals\u2019 self-reported knowledge, attitudes, and behaviors related to pregnancy prevention program materials for valproate-containing medicines. Pharmacy. 2024;12:182.","journal-title":"Pharmacy"},{"key":"1207_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/14740338.2021.1933429","volume":"20","author":"JE Hughes","year":"2021","unstructured":"Hughes JE, Buckley N, Looney Y, Kirwan G, Curran S, Doherty CP, et al. Awareness, knowledge and practice of healthcare professionals following implementation of a Pregnancy Prevention Program for sodium valproate in Ireland: a multi-stakeholder cross-sectional study. Expert Opin Drug Saf. 2021;20:965\u201377.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Drugs & Therapy Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-025-01207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40267-025-01207-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-025-01207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:45:14Z","timestamp":1764776714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40267-025-01207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":13,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s40267-025-01207-8","relation":{},"ISSN":["1172-0360","1179-1977"],"issn-type":[{"type":"print","value":"1172-0360"},{"type":"electronic","value":"1179-1977"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was granted by the ethics committee of the Faculty of Medicine of the University of Porto (Ethics committee process CE 407-19). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained at the start of the survey. For the interview, informed consent was sought in advance via email.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. The questionnaire responses and the interviews conducted did not collect any data that could identify participants and were recorded anonymously and handled in accordance with the General Data Protection Regulation (GDPR) (EU) 2016\/679 of 27 April 2016.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are available in an institutional repository and will be provided upon request during peer review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Survey development, implementation, and analysis were centrally managed within the international study \u201cImpact of EU label changes and PPP for medicinal products containing valproate and related substances: risk awareness and adherence (ValproateRiskAware)\u201d. Paula Sousa-Ferreira contributed to the review of the study design, survey design, and translation, as well as to Portuguese data collection, the review of data analysis, and the preparation of the first draft of the manuscript and subsequent versions. In\u00eas Ribeiro was involved in the review of the study design, survey design, and translation, as well as in Portuguese data collection and the review of data analysis. Teresa Leonardo Alves contributed to the conceptualisation, design, survey design, analysis, data interpretation, draft review, and final approval. All authors (Paula Sousa-Ferreira, In\u00eas Ribeiro, Teresa Leonardo Alves, Jo\u00e3o Rocha, Carla Torre) participated in data interpretation, reviewed all drafts of the manuscript, and provided feedback. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}